Non-injectable Insulin Market Overview, Outlook, Size, Share 2024-2033 |

The non-injectable insulin market size has grown rapidly in recent years. It will grow from $1.71 billion in 2023 to $1.92 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to patient compliance improvement, addressing needle phobia, quality of life enhancement, ease of administration, and stable blood glucose control.

The non-injectable insulin market size is expected to see rapid growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to continued patient compliance emphasis, persistent needle phobia solutions, further quality of life improvements, continuous safety enhancement, and reduced infection and injury risks. Major trends in the forecast period include technological advancements, evolution of technological solutions, digital health integration, nanotechnology applications, and combination therapies.

Market Overview -
Non-injectable insulin is a type of insulin that can be administered into the body without the need for injection. These non-injectable forms of insulin aim to offer alternatives to traditional injections, making diabetes management more accessible and potentially improving the overall quality of life for individuals with diabetes.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Expanding Non-Injectable Insulin Market Fueled by Escalating Obesity and Diabetes Epidemics
The rising obesity and diabetes issues are expected to propel the growth of the non-injectable insulin market going forward. Obesity is a condition characterized by excessive accumulation of body fat, usually resulting from an imbalance between energy intake (calories consumed) and energy expenditure, while diabetes mellitus, often referred to simply as diabetes, is a group of metabolic disorders characterized by high blood sugar levels over a prolonged period. Non-injectable insulin is used to treat diabetes and obesity, with the potential to improve management by addressing barriers to insulin therapy, offering potential weight management benefits, and providing more convenient treatment options. For instance, in 2022, according to the World Heart Federation, a Switzerland-based non-governmental organization, global obesity rates are expected to surge, with an estimated 2.3 billion people in 2021, including children and adults, facing overweight and obesity, this is likely to rise to 2.7 billion by 2025. Furthermore, in April 2023, according to a report published by the British Diabetic Association, a UK-based diabetes charity, in the UK, 4.3 million individuals have diabetes, and more than 2.4 million people in the UK are at high risk of acquiring type 2 diabetes. Registration numbers for 2021-22 are up 148,951 from 2020-21. Therefore, rising obesity and diabetes issues are driving the growth of the non-injectable insulin market.

Competitive Landscape -
Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

Innovative Advancements In Non-Injectable Insulin Delivery
Major companies operating in the non-injectable insulin market are focusing on innovative advancements in drug delivery technologies, such as needle-free oral insulin spray, to improve the lives of people who manage their diabetes with multiple insulin injections. A needle-free insulin spray is a painless and needle-free alternative for regulating blood glucose, offering a convenient option as the doses can be sprayed directly into the mouth. For instance, in November 2023, NiedlFree Technologies, an India-based technology platform, introduced Ozulin, an oral insulin spray. This oral insulin spray is intended to provide a more user-friendly solution for individuals with diabetes, particularly those who may find traditional injectable insulin methods challenging. If approved, Ozulin has the potential to be a game-changer for diabetics, offering a more convenient and pain-free alternative to insulin injections.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Key Segments -

The non-injectable insulin market covered in this report is segmented -

1) By Type: Synthetic Insulin, Semi Synthetic Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Key highlights covered in the report -

1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.